METTL14 may inhibit HCC progression by altering the m6A modification of cysteine sulfonic acid deacidiase (CSAD), glutamic-oxaloacetic transaminase 2 (GOT2) and SOCS2 (109). Here, SOCS2 is linked to hepatocellular carcinoma.